Eric Venker Biography and Net Worth

COO of Roivant Sciences

Dr. Eric Venker serves as Chief Operating Officer of Roivant Sciences. Dr. Venker first joined Roivant in 2014 and has since served in various roles of increasing responsibility, including Chief of Staff to the CEO. Prior to joining Roivant, Dr. Venker was a physician at New York Presbyterian Hospital, Columbia University Medical Center, where he trained in internal medicine. While there, Eric served as the Chair of the Housestaff Quality Council and led operational initiatives to improve efficiencies across a large hospital system with $5 billion in annual revenue. Earlier in his career, Eric was a Clinical Pharmacist at Yale-New Haven Hospital. He received his Pharm.D. from St. Louis College of Pharmacy and his M.D. from Yale School of Medicine.

What is Eric Venker's net worth?: The estimated net worth of Eric Venker is at least $10.33 million as of March 20th, 2025. Dr. Venker owns 959,457 shares of Roivant Sciences stock worth more than $10,330,474 as of March 25th. This net worth estimate does not reflect any other assets that Dr. Venker may own. Additionally, Dr. Venker receives a salary of $1,280,000.00 as COO at Roivant Sciences. Learn More about Eric Venker's net worth.
How old is Eric Venker?: Dr. Venker is currently 37 years old. There are 5 older executives and no younger executives at Roivant Sciences. The oldest executive at Roivant Sciences is Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management, who is 56 years old. Learn More on Eric Venker's age.
What is Eric Venker's salary?: As the COO of Roivant Sciences Ltd., Dr. Venker earns $1,280,000.00 per year. There are 2 executives that earn more than Dr. Venker. The highest earning executive at Roivant Sciences is Mr. Matthew Gline, CEO & Director, who commands a salary of $1,770,000.00 per year. Learn More on Eric Venker's salary.
How do I contact Eric Venker?: The corporate mailing address for Dr. Venker and other Roivant Sciences executives is Clarendon House, 2 Church Street, Hamilton Parish HM 11. Roivant Sciences can also be reached via phone at 44-20-7400-3347 and via email at ir@roivant.com. Learn More on Eric Venker's contact information.
Has Eric Venker been buying or selling shares of Roivant Sciences?: In the last ninety days, Eric Venker has sold $12,655,712.50 of Roivant Sciences stock. Most recently, Eric Venker sold 434,478 shares of the business's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $10.82, for a transaction totalling $4,701,051.96. Following the completion of the sale, the chief operating officer now directly owns 1,127,290 shares of the company's stock, valued at $12,197,277.80. Learn More on Eric Venker's trading history.
Who are Roivant Sciences' active insiders?: Roivant Sciences' insider roster includes Matthew Gline (CEO), Rakhi Kumar (CAO), Keith Manchester (Director), Mayukh Sukhatme (President and Chief Investment Officer), and Eric Venker (COO). Learn More on Roivant Sciences' active insiders.
Are insiders buying or selling shares of Roivant Sciences?: In the last year, Roivant Sciences insiders bought shares 1 times. They purchased a total of 16,845,010 shares worth more than $336,900,200.00. In the last year, insiders at the sold shares 18 times. They sold a total of 6,815,479 shares worth more than $79,086,208.08. The most recent insider tranaction occured on March, 24th when COO Eric Venker sold 434,478 shares worth more than $4,701,051.96. Insiders at Roivant Sciences own 7.9% of the company. Learn More about insider trades at Roivant Sciences.
Information on this page was last updated on 3/24/2025.

Eric Venker Insider Trading History at Roivant Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/24/2025	Sell	434,478	$10.82	$4,701,051.96	1,127,290
3/20/2025	Sell	315,522	$11.06	$3,489,673.32	959,457
2/20/2025	Sell	100,000	$10.65	$1,065,000.00	896,869
2/13/2025	Sell	218,041	$10.42	$2,271,987.22	896,869
1/21/2025	Sell	100,000	$11.28	$1,128,000.00	732,294
12/30/2024	Sell	177,704	$11.54	$2,050,704.16	740,976
12/27/2024	Sell	176,900	$11.82	$2,090,958.00	668,680
12/20/2024	Sell	100,000	$11.49	$1,149,000.00	595,580
11/20/2024	Sell	100,000	$11.32	$1,132,000.00	606,525
10/21/2024	Sell	100,000	$11.65	$1,165,000.00	617,470
2/9/2024	Sell	96,950	$10.92	$1,058,694.00	532,207
10/5/2023	Sell	153,027	$10.11	$1,547,102.97	595,397
10/2/2023	Sell	440,752	$10.80	$4,760,121.60	595,397
9/27/2023	Sell	500,000	$13.02	$6,510,000.00	595,397
9/8/2023	Sell	106,430	$12.19	$1,297,381.70	611,813
9/6/2023	Sell	5,926	$11.85	$70,223.10	611,813
9/1/2023	Sell	14,763	$11.90	$175,679.70	611,813
8/14/2023	Sell	59,811	$11.89	$711,152.79	627,918
8/2/2023	Sell	16,397	$11.86	$194,468.42	627,918
7/31/2023	Sell	117,372	$11.91	$1,397,900.52	627,918
7/26/2023	Sell	73,568	$10.91	$802,626.88	627,918
7/24/2023	Sell	33,081	$10.93	$361,575.33	644,215
7/21/2023	Sell	181,998	$11.13	$2,025,637.74	644,215
6/9/2023	Sell	299,384	$9.91	$2,966,895.44	660,097
6/7/2023	Sell	201	$9.85	$1,979.85	660,097
5/23/2023	Sell	415	$9.85	$4,087.75	675,768
5/8/2023	Sell	61,206	$8.93	$546,569.58	675,768
5/4/2023	Sell	88,838	$8.30	$737,355.40	675,768
5/2/2023	Sell	109,074	$8.29	$904,223.46	675,768
4/27/2023	Sell	73,514	$8.51	$625,604.14	675,768
1/5/2023	Sell	24,037	$8.02	$192,776.74	729,429
1/3/2023	Sell	95,484	$7.32	$698,942.88	753,466
12/8/2022	Sell	11,729	$7.00	$82,103.00	1,022,118
10/25/2022	Sell	15,922	$4.40	$70,056.80	1,049,850
9/23/2022	Sell	17,392	$3.07	$53,393.44	1,065,772
8/24/2022	Sell	16,530	$3.71	$61,326.30	1,083,164
7/25/2022	Sell	16,896	$4.33	$73,159.68	1,099,694
6/23/2022	Sell	16,402	$4.34	$71,184.68	1,116,590
5/20/2022	Sell	136,421	$3.70	$504,757.70	1,132,992
4/25/2022	Sell	5,107	$3.84	$19,610.88	1,269,413
3/30/2022	Sell	19,336	$4.84	$93,586.24
3/25/2022	Sell	80,045	$5.06	$405,027.70

See Full Table

Eric Venker Buying and Selling Activity at Roivant Sciences

Roivant Sciences Company Overview

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Today's Range

Now: $10.67

$10.60

$10.91

50 Day Range

MA: $10.79

$10.17

$11.37

2 Week Range

Now: $10.67

$9.93

$13.06

Volume

6,588,854 shs

Average Volume

5,635,938 shs

Market Capitalization

$7.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Eric Venker Biography and Net Worth

What is Eric Venker's net worth?

How old is Eric Venker?

What is Eric Venker's salary?

How do I contact Eric Venker?

Has Eric Venker been buying or selling shares of Roivant Sciences?

Who are Roivant Sciences' active insiders?

Are insiders buying or selling shares of Roivant Sciences?